Novo Nordisk agreed to license Vivtex’s gastrointestinal screening and formulation platform in a deal potentially worth up to $2.1 billion plus tiered royalties to pursue oral peptide and protein therapeutics for obesity, diabetes and related metabolic conditions. Vivtex — spun out of MIT with founders including Robert Langer and Giovanni Traverso — will provide delivery technology and early R&D support before Novo assumes global development, regulatory, manufacturing and commercialization. The transaction signals large pharma’s continued push to convert injectable biologics into oral formats.